Pieris Pharmaceuticals to Host Investor Call Today to Discuss Servier Collaboration
Pieris Pharmaceuticals, Inc | January 05, 2017
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer and other diseases, announced it will host an investor conference call today at 8:30 AM (EST) to discuss its strategic immuno-oncology co-development collaboration with Servier.